{"success":true,"data":{"pressRelease":{"id":"163138","rtpr_id":"nGNX5jB4HZ-20261007","ticker":"AIAI","exchange":"TSX","all_tickers":["AIAI"],"title":"NetraMark Founder Dr. Joseph Geraci to Participate in H.C. Wainwright’s AI-Based Drug Discovery and Development Conference","author":"Globe Newswire","published_at":"2026-10-07T12:38:38.091Z","article_body":"* Panel discussion to explore competitive differentiation as AI reshapes drug\ndiscovery and development\nTORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc\n(https://www.globenewswire.com/Tracker?data=qoZy02YqMGDDAijdA5ScP79ZSnPioVkVvPn1w62LvO_HlrekwGkNWiv_TTs_4ocmX6Y36U__-d83pHeDriog05EsS8OmcjsFvf7kIjcYmP8=).\n(the \"Company\" or \"NetraMark\") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a\nclinical intelligence company transforming clinical trials with AI-powered\nprecision analytics in the pharmaceutical industry, today announced that Dr.\nJoseph Geraci, Founder and Chief Scientific and Technical Officer, will\nparticipate in the H.C. Wainwright 3rd Annual AI Based Drug Discovery and\nDevelopment Virtual Conference, taking place October 8–9, 2026.\n\nDr. Geraci will join the panel “Design Got Cheap - Where Is the Defensible\nMoat?”, scheduled for 4:00–5:00 p.m. Eastern Time. Fellow panelists\ninclude Peyton Greenside, CEO and Co-founder of BigHat Biosciences, and\nJennifer Bath, CEO of MindWalk AI. The discussion will be moderated by\nSwayampakula Ramakanth, Managing Director at H.C. Wainwright & Co.\n\nThe panel’s focus on competitive differentiation is particularly relevant to\nNetraMark’s approach to clinical development. Its proprietary NetraAI\nplatform is designed to uncover explainable patient subpopulations within the\nsmall, heterogeneous datasets common in clinical trials. These insights seek\nto help sponsors understand differences in treatment response, placebo\nresponse and adverse events, informing patient selection and subsequent trial\ndesign.\n\n“As AI makes it more efficient to generate drug candidates, a critical\nchallenge remains: understanding which patients are most likely to benefit and\nhow to demonstrate that benefit in a clinical trial,” said Dr. Geraci. “At\nNetraMark, our differentiated approach allows us to seek extract insights\nabout patient populations that AI generally struggles with. This represents an\nimportant defensible moat that will augment AI’s capabilities in this\nfield.”\n\nThe virtual conference brings together biotechnology and pharmaceutical\ncompanies, institutional investors and industry executives to discuss\ndevelopments in AI-based drug discovery and development.\n\nTo register and view conference information, visit: Conference Registration\n(https://www.globenewswire.com/Tracker?data=SVM0R6xR_mZqFIofCgcXKwiNzO80boAc6zdOPSevj9IslD2rWCtyGAYfrZHxvHDGORWqrnLSfq_XfvBjOWH0DdDCn5KOoaKGMMRMcgbprbdOpS3jtTg-rWgMPSUfberYehJ12jGwc-_uuGBok_asCA==)\n\nFor more information on NetraMark and NetraAI, visit www.netramark.com.\n\nAbout NetraAI\nNetraAI is engineered to include focus mechanisms that separate small datasets\ninto explainable and unexplainable subsets. Unexplainable subsets are\ncollections of patients that can lead to suboptimal overfit models and\ninaccurate insights due to poor correlations with the variables involved.\nNetraAI uses explainable subsets to derive insights and hypotheses (including\nfactors that influence treatment and placebo responses and adverse events),\npotentially increasing the likelihood of a clinical trial's success. Many\nother AI methods lack these focus mechanisms and assign every patient to a\nclass, often leading to \"overfitting,\" which drowns out critical information\nthat could have been used to improve a trial's chance of success.\n\nAbout NetraMark\nNetraMark is focused on being a leader in the development of Generative\nArtificial Intelligence (Gen AI)/Machine Learning (ML) solutions that are\ntargeted at the biotechnology and pharmaceutical industries. The Company's\nproduct offering uses a novel topology-based algorithm that has the ability to\nparse patient data sets into subsets of people that are strongly related\naccording to several variables simultaneously. This allows NetraMark to use a\nvariety of ML methods, depending on the character and size of the data, to\ntransform the data into powerfully intelligent data that activates traditional\nAI/ML methods. The result is that NetraMark can work with much smaller\ndatasets often prevalent in clinical trials, and accurately segment diseases\ninto different types, as well as help to classify patients for sensitivity to\ndrugs and/or efficacy of treatment.\n\nFor further details on the Company please see the Company's publicly available\ndocuments filed on the System for Electronic Document Analysis and Retrieval+\n(SEDAR+).\n\nForward-Looking Statements\nThis press release contains \"forward-looking information\" within the meaning\nof applicable Canadian securities legislation including statements regarding\nthe potential for insights from NetraAI to help sponsors understand\ndifferences in treatment response, placebo response and adverse events,\ninforming patient selection and subsequent trial design and the benefits of\nNetraMark’s differentiation over other AI tools to create a defensible moat.\nForward-looking information can be identified by the use of forward-looking\nterminology such as \"expect\", \"likely\", \"may\", \"will\", \"should\", \"intend\",\n\"anticipate\", \"potential\", \"proposed\", \"estimate\" and other similar words,\nincluding negative and grammatical variations thereof, or statements that\ncertain events or conditions \"may\", \"would\" or \"will\" happen, or by\ndiscussions of strategy. Forward-looking information includes estimates,\nplans, expectations, opinions, forecasts, projections, targets, guidance, or\nother statements that are not statements of fact. The forward-looking\nstatements are expectations only and are subject to known and unknown risks,\nuncertainties and other important factors that could cause actual results of\nthe Company or industry results to differ materially from future results,\nperformance or achievements. Any forward-looking information speaks only as of\nthe date on which it is made, and, except as required by law, NetraMark does\nnot undertake any obligation to update or revise any forward-looking\ninformation, whether as a result of new information, future events, or\notherwise. New factors emerge from time to time, and it is not possible for\nNetraMark to predict all such factors.\n\nWhen considering these forward-looking statements, readers should keep in mind\nthe risk factors and other cautionary statements as set out in the materials\nwe file with applicable Canadian securities regulatory authorities on SEDAR+\nat www.sedarplus.com including our Annual Information Form for the year ended\nSeptember 30, 2025. These risk factors and other factors could cause actual\nevents or results to differ materially from those described in any\nforward-looking information. The Toronto Stock Exchange does not accept\nresponsibility for the adequacy or accuracy of this release.\n\nContact Information:\nSwapan Kakumanu - CFO | swapan@netramark.com | 403-681-2549\n\nMedia Contact:\nnetramark@ampublicrelations.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d65cf3f8-cf9c-475c-b740-09a659269da4)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5jB4HZ-20261007","title":"NetraMark Founder Dr. Joseph Geraci to Participate in H.C. Wainwright’s AI-Based Drug Discovery and Development Conference","author":"Globe Newswire","ticker":"AIAI","created":"2026-10-07T12:38:38.091Z","tickers":["AIAI"],"exchange":"TSX","article_body":"* Panel discussion to explore competitive differentiation as AI reshapes drug\ndiscovery and development\nTORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc\n(https://www.globenewswire.com/Tracker?data=qoZy02YqMGDDAijdA5ScP79ZSnPioVkVvPn1w62LvO_HlrekwGkNWiv_TTs_4ocmX6Y36U__-d83pHeDriog05EsS8OmcjsFvf7kIjcYmP8=).\n(the \"Company\" or \"NetraMark\") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a\nclinical intelligence company transforming clinical trials with AI-powered\nprecision analytics in the pharmaceutical industry, today announced that Dr.\nJoseph Geraci, Founder and Chief Scientific and Technical Officer, will\nparticipate in the H.C. Wainwright 3rd Annual AI Based Drug Discovery and\nDevelopment Virtual Conference, taking place October 8–9, 2026.\n\nDr. Geraci will join the panel “Design Got Cheap - Where Is the Defensible\nMoat?”, scheduled for 4:00–5:00 p.m. Eastern Time. Fellow panelists\ninclude Peyton Greenside, CEO and Co-founder of BigHat Biosciences, and\nJennifer Bath, CEO of MindWalk AI. The discussion will be moderated by\nSwayampakula Ramakanth, Managing Director at H.C. Wainwright & Co.\n\nThe panel’s focus on competitive differentiation is particularly relevant to\nNetraMark’s approach to clinical development. Its proprietary NetraAI\nplatform is designed to uncover explainable patient subpopulations within the\nsmall, heterogeneous datasets common in clinical trials. These insights seek\nto help sponsors understand differences in treatment response, placebo\nresponse and adverse events, informing patient selection and subsequent trial\ndesign.\n\n“As AI makes it more efficient to generate drug candidates, a critical\nchallenge remains: understanding which patients are most likely to benefit and\nhow to demonstrate that benefit in a clinical trial,” said Dr. Geraci. “At\nNetraMark, our differentiated approach allows us to seek extract insights\nabout patient populations that AI generally struggles with. This represents an\nimportant defensible moat that will augment AI’s capabilities in this\nfield.”\n\nThe virtual conference brings together biotechnology and pharmaceutical\ncompanies, institutional investors and industry executives to discuss\ndevelopments in AI-based drug discovery and development.\n\nTo register and view conference information, visit: Conference Registration\n(https://www.globenewswire.com/Tracker?data=SVM0R6xR_mZqFIofCgcXKwiNzO80boAc6zdOPSevj9IslD2rWCtyGAYfrZHxvHDGORWqrnLSfq_XfvBjOWH0DdDCn5KOoaKGMMRMcgbprbdOpS3jtTg-rWgMPSUfberYehJ12jGwc-_uuGBok_asCA==)\n\nFor more information on NetraMark and NetraAI, visit www.netramark.com.\n\nAbout NetraAI\nNetraAI is engineered to include focus mechanisms that separate small datasets\ninto explainable and unexplainable subsets. Unexplainable subsets are\ncollections of patients that can lead to suboptimal overfit models and\ninaccurate insights due to poor correlations with the variables involved.\nNetraAI uses explainable subsets to derive insights and hypotheses (including\nfactors that influence treatment and placebo responses and adverse events),\npotentially increasing the likelihood of a clinical trial's success. Many\nother AI methods lack these focus mechanisms and assign every patient to a\nclass, often leading to \"overfitting,\" which drowns out critical information\nthat could have been used to improve a trial's chance of success.\n\nAbout NetraMark\nNetraMark is focused on being a leader in the development of Generative\nArtificial Intelligence (Gen AI)/Machine Learning (ML) solutions that are\ntargeted at the biotechnology and pharmaceutical industries. The Company's\nproduct offering uses a novel topology-based algorithm that has the ability to\nparse patient data sets into subsets of people that are strongly related\naccording to several variables simultaneously. This allows NetraMark to use a\nvariety of ML methods, depending on the character and size of the data, to\ntransform the data into powerfully intelligent data that activates traditional\nAI/ML methods. The result is that NetraMark can work with much smaller\ndatasets often prevalent in clinical trials, and accurately segment diseases\ninto different types, as well as help to classify patients for sensitivity to\ndrugs and/or efficacy of treatment.\n\nFor further details on the Company please see the Company's publicly available\ndocuments filed on the System for Electronic Document Analysis and Retrieval+\n(SEDAR+).\n\nForward-Looking Statements\nThis press release contains \"forward-looking information\" within the meaning\nof applicable Canadian securities legislation including statements regarding\nthe potential for insights from NetraAI to help sponsors understand\ndifferences in treatment response, placebo response and adverse events,\ninforming patient selection and subsequent trial design and the benefits of\nNetraMark’s differentiation over other AI tools to create a defensible moat.\nForward-looking information can be identified by the use of forward-looking\nterminology such as \"expect\", \"likely\", \"may\", \"will\", \"should\", \"intend\",\n\"anticipate\", \"potential\", \"proposed\", \"estimate\" and other similar words,\nincluding negative and grammatical variations thereof, or statements that\ncertain events or conditions \"may\", \"would\" or \"will\" happen, or by\ndiscussions of strategy. Forward-looking information includes estimates,\nplans, expectations, opinions, forecasts, projections, targets, guidance, or\nother statements that are not statements of fact. The forward-looking\nstatements are expectations only and are subject to known and unknown risks,\nuncertainties and other important factors that could cause actual results of\nthe Company or industry results to differ materially from future results,\nperformance or achievements. Any forward-looking information speaks only as of\nthe date on which it is made, and, except as required by law, NetraMark does\nnot undertake any obligation to update or revise any forward-looking\ninformation, whether as a result of new information, future events, or\notherwise. New factors emerge from time to time, and it is not possible for\nNetraMark to predict all such factors.\n\nWhen considering these forward-looking statements, readers should keep in mind\nthe risk factors and other cautionary statements as set out in the materials\nwe file with applicable Canadian securities regulatory authorities on SEDAR+\nat www.sedarplus.com including our Annual Information Form for the year ended\nSeptember 30, 2025. These risk factors and other factors could cause actual\nevents or results to differ materially from those described in any\nforward-looking information. The Toronto Stock Exchange does not accept\nresponsibility for the adequacy or accuracy of this release.\n\nContact Information:\nSwapan Kakumanu - CFO | swapan@netramark.com | 403-681-2549\n\nMedia Contact:\nnetramark@ampublicrelations.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d65cf3f8-cf9c-475c-b740-09a659269da4)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-07T12:38:38.131193452Z","server_sent_at_ms":1791376718131},"received_at":"2026-10-07T12:38:38.181Z","source_url":null},"analysis":{"id":"151599","press_release_id":"163138","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"NetraMark founder Dr. Joseph Geraci will join a panel at H.C. Wainwright's 3rd Annual AI Based Drug Discovery and Development Virtual Conference on October 8-9, 2026.\n\nThe panel, 'Design Got Cheap - Where Is the Defensible Moat?', focuses on competitive differentiation as AI reshapes drug discovery, with panelists from BigHat Biosciences and MindWalk AI.\n\nNetraMark will use the platform to highlight its NetraAI platform, which segments small heterogeneous clinical-trial datasets into explainable patient subpopulations. The announcement is a visibility event with no financial impact.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Micro-cap AI clinical-analytics firm gets investor-conference visibility; watch for follow-on business updates."},"keyFigures":{},"quotedText":"As AI makes it more efficient to generate drug candidates, a critical challenge remains: understanding which patients are most likely to benefit and how to demonstrate that benefit in a clinical trial","namedEntities":{"people":[{"name":"Dr. Joseph Geraci","role":"Founder and Chief Scientific and Technical Officer"},{"name":"Peyton Greenside","role":"CEO and Co-founder of BigHat Biosciences"},{"name":"Jennifer Bath","role":"CEO of MindWalk AI"},{"name":"Swayampakula Ramakanth","role":"Managing Director at H.C. Wainwright & Co."}],"products":["NetraAI"],"companies":[{"name":"NetraMark Holdings Inc","ticker":"AIAI"},{"name":"H.C. Wainwright & Co.","relationship":"conference host/moderator"},{"name":"BigHat Biosciences","relationship":"panel participant"},{"name":"MindWalk AI","relationship":"panel participant"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Conference panel participation announcement with no financial results, guidance, or transactional content. Promotional visibility event only."},"tickerRelevance":{"others":[],"primary":"AIAI"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"conference-participation","issuerAuthored":true,"marketCapAdjustment":"small cap discount"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"NetraMark founder Dr. Joseph Geraci will join a panel at H.C. Wainwright's 3rd Annual AI Based Drug Discovery and Development Virtual Conference on October 8-9, 2026.\n\nThe panel, 'Design Got Cheap - Where Is the Defensible Moat?', focuses on competitive differentiation as AI reshapes drug discovery, with panelists from BigHat Biosciences and MindWalk AI.\n\nNetraMark will use the platform to highlight its NetraAI platform, which segments small heterogeneous clinical-trial datasets into explainable patient subpopulations. The announcement is a visibility event with no financial impact.","key_figures":{},"named_entities":{"people":[{"name":"Dr. Joseph Geraci","role":"Founder and Chief Scientific and Technical Officer"},{"name":"Peyton Greenside","role":"CEO and Co-founder of BigHat Biosciences"},{"name":"Jennifer Bath","role":"CEO of MindWalk AI"},{"name":"Swayampakula Ramakanth","role":"Managing Director at H.C. Wainwright & Co."}],"products":["NetraAI"],"companies":[{"name":"NetraMark Holdings Inc","ticker":"AIAI"},{"name":"H.C. Wainwright & Co.","relationship":"conference host/moderator"},{"name":"BigHat Biosciences","relationship":"panel participant"},{"name":"MindWalk AI","relationship":"panel participant"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-07T12:38:43.341Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"conference-participation","issuerAuthored":true,"marketCapAdjustment":"small cap discount"}},"durationMs":4953,"modelName":"glm-5.3-flashx"}}